The global Adeno-Associated Virus (AAV) CDMO Services market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
United States market for Adeno-Associated Virus (AAV) CDMO Services is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Adeno-Associated Virus (AAV) CDMO Services is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Adeno-Associated Virus (AAV) CDMO Services is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Adeno-Associated Virus (AAV) CDMO Services players cover Thermo Fisher Scientific, GenScript ProBio, Hillgene, Charles River Laboratories, Ubrigene, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
The 鈥淎deno-Associated Virus (AAV) CDMO Services Industry Forecast鈥� looks at past sales and reviews total world Adeno-Associated Virus (AAV) CDMO Services sales in 2024, providing a comprehensive analysis by region and market sector of projected Adeno-Associated Virus (AAV) CDMO Services sales for 2025 through 2031. With Adeno-Associated Virus (AAV) CDMO Services sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Adeno-Associated Virus (AAV) CDMO Services industry.
This Insight Report provides a comprehensive analysis of the global Adeno-Associated Virus (AAV) CDMO Services landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Adeno-Associated Virus (AAV) CDMO Services portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Adeno-Associated Virus (AAV) CDMO Services market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Adeno-Associated Virus (AAV) CDMO Services and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Adeno-Associated Virus (AAV) CDMO Services.
This report presents a comprehensive overview, market shares, and growth opportunities of Adeno-Associated Virus (AAV) CDMO Services market by product type, application, key players and key regions and countries.
Segmentation by Type:
IIT Grade
IND Grade
Clinical Trial Grade
Commercial Production Grade
Segmentation by Application:
Biopharmaceutical Company
Academic Scientific Research Institution
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Thermo Fisher Scientific
GenScript ProBio
Hillgene
Charles River Laboratories
Ubrigene
Obio Technology (Shanghai)
Genesail Biotech (Shanghai)
WuXi ATU
Porton Advanced Solutions
Pharmaron
Asymchem Laboratories (Tianjin)
Merck
VectorBuilder
Yposkesi
Flash Therapeutics
VIVEBiotech
Miltenyi Bioindustry
Genezen
Miltenyi Biotec
Exthera
Catalent
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Adeno-Associated Virus (AAV) CDMO Services 麻豆原创 Size (2020-2031)
2.1.2 Adeno-Associated Virus (AAV) CDMO Services 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Adeno-Associated Virus (AAV) CDMO Services by Country/Region (2020, 2024 & 2031)
2.2 Adeno-Associated Virus (AAV) CDMO Services Segment by Type
2.2.1 IIT Grade
2.2.2 IND Grade
2.2.3 Clinical Trial Grade
2.2.4 Commercial Production Grade
2.3 Adeno-Associated Virus (AAV) CDMO Services 麻豆原创 Size by Type
2.3.1 Adeno-Associated Virus (AAV) CDMO Services 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Adeno-Associated Virus (AAV) CDMO Services 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Adeno-Associated Virus (AAV) CDMO Services Segment by Application
2.4.1 Biopharmaceutical Company
2.4.2 Academic Scientific Research Institution
2.5 Adeno-Associated Virus (AAV) CDMO Services 麻豆原创 Size by Application
2.5.1 Adeno-Associated Virus (AAV) CDMO Services 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Adeno-Associated Virus (AAV) CDMO Services 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Adeno-Associated Virus (AAV) CDMO Services 麻豆原创 Size by Player
3.1 Adeno-Associated Virus (AAV) CDMO Services 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Adeno-Associated Virus (AAV) CDMO Services Revenue by Player (2020-2025)
3.1.2 Global Adeno-Associated Virus (AAV) CDMO Services Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Adeno-Associated Virus (AAV) CDMO Services Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Adeno-Associated Virus (AAV) CDMO Services by Region
4.1 Adeno-Associated Virus (AAV) CDMO Services 麻豆原创 Size by Region (2020-2025)
4.2 Global Adeno-Associated Virus (AAV) CDMO Services Annual Revenue by Country/Region (2020-2025)
4.3 Americas Adeno-Associated Virus (AAV) CDMO Services 麻豆原创 Size Growth (2020-2025)
4.4 APAC Adeno-Associated Virus (AAV) CDMO Services 麻豆原创 Size Growth (2020-2025)
4.5 Europe Adeno-Associated Virus (AAV) CDMO Services 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Adeno-Associated Virus (AAV) CDMO Services 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Adeno-Associated Virus (AAV) CDMO Services 麻豆原创 Size by Country (2020-2025)
5.2 Americas Adeno-Associated Virus (AAV) CDMO Services 麻豆原创 Size by Type (2020-2025)
5.3 Americas Adeno-Associated Virus (AAV) CDMO Services 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Adeno-Associated Virus (AAV) CDMO Services 麻豆原创 Size by Region (2020-2025)
6.2 APAC Adeno-Associated Virus (AAV) CDMO Services 麻豆原创 Size by Type (2020-2025)
6.3 APAC Adeno-Associated Virus (AAV) CDMO Services 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Adeno-Associated Virus (AAV) CDMO Services 麻豆原创 Size by Country (2020-2025)
7.2 Europe Adeno-Associated Virus (AAV) CDMO Services 麻豆原创 Size by Type (2020-2025)
7.3 Europe Adeno-Associated Virus (AAV) CDMO Services 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Adeno-Associated Virus (AAV) CDMO Services by Region (2020-2025)
8.2 Middle East & Africa Adeno-Associated Virus (AAV) CDMO Services 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Adeno-Associated Virus (AAV) CDMO Services 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Adeno-Associated Virus (AAV) CDMO Services 麻豆原创 Forecast
10.1 Global Adeno-Associated Virus (AAV) CDMO Services Forecast by Region (2026-2031)
10.1.1 Global Adeno-Associated Virus (AAV) CDMO Services Forecast by Region (2026-2031)
10.1.2 Americas Adeno-Associated Virus (AAV) CDMO Services Forecast
10.1.3 APAC Adeno-Associated Virus (AAV) CDMO Services Forecast
10.1.4 Europe Adeno-Associated Virus (AAV) CDMO Services Forecast
10.1.5 Middle East & Africa Adeno-Associated Virus (AAV) CDMO Services Forecast
10.2 Americas Adeno-Associated Virus (AAV) CDMO Services Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Adeno-Associated Virus (AAV) CDMO Services Forecast
10.2.2 Canada 麻豆原创 Adeno-Associated Virus (AAV) CDMO Services Forecast
10.2.3 Mexico 麻豆原创 Adeno-Associated Virus (AAV) CDMO Services Forecast
10.2.4 Brazil 麻豆原创 Adeno-Associated Virus (AAV) CDMO Services Forecast
10.3 APAC Adeno-Associated Virus (AAV) CDMO Services Forecast by Region (2026-2031)
10.3.1 China Adeno-Associated Virus (AAV) CDMO Services 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Adeno-Associated Virus (AAV) CDMO Services Forecast
10.3.3 Korea 麻豆原创 Adeno-Associated Virus (AAV) CDMO Services Forecast
10.3.4 Southeast Asia 麻豆原创 Adeno-Associated Virus (AAV) CDMO Services Forecast
10.3.5 India 麻豆原创 Adeno-Associated Virus (AAV) CDMO Services Forecast
10.3.6 Australia 麻豆原创 Adeno-Associated Virus (AAV) CDMO Services Forecast
10.4 Europe Adeno-Associated Virus (AAV) CDMO Services Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Adeno-Associated Virus (AAV) CDMO Services Forecast
10.4.2 France 麻豆原创 Adeno-Associated Virus (AAV) CDMO Services Forecast
10.4.3 UK 麻豆原创 Adeno-Associated Virus (AAV) CDMO Services Forecast
10.4.4 Italy 麻豆原创 Adeno-Associated Virus (AAV) CDMO Services Forecast
10.4.5 Russia 麻豆原创 Adeno-Associated Virus (AAV) CDMO Services Forecast
10.5 Middle East & Africa Adeno-Associated Virus (AAV) CDMO Services Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Adeno-Associated Virus (AAV) CDMO Services Forecast
10.5.2 South Africa 麻豆原创 Adeno-Associated Virus (AAV) CDMO Services Forecast
10.5.3 Israel 麻豆原创 Adeno-Associated Virus (AAV) CDMO Services Forecast
10.5.4 Turkey 麻豆原创 Adeno-Associated Virus (AAV) CDMO Services Forecast
10.6 Global Adeno-Associated Virus (AAV) CDMO Services Forecast by Type (2026-2031)
10.7 Global Adeno-Associated Virus (AAV) CDMO Services Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Adeno-Associated Virus (AAV) CDMO Services Forecast
11 Key Players Analysis
11.1 Thermo Fisher Scientific
11.1.1 Thermo Fisher Scientific Company Information
11.1.2 Thermo Fisher Scientific Adeno-Associated Virus (AAV) CDMO Services Product Offered
11.1.3 Thermo Fisher Scientific Adeno-Associated Virus (AAV) CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Thermo Fisher Scientific Main Business Overview
11.1.5 Thermo Fisher Scientific Latest Developments
11.2 GenScript ProBio
11.2.1 GenScript ProBio Company Information
11.2.2 GenScript ProBio Adeno-Associated Virus (AAV) CDMO Services Product Offered
11.2.3 GenScript ProBio Adeno-Associated Virus (AAV) CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 GenScript ProBio Main Business Overview
11.2.5 GenScript ProBio Latest Developments
11.3 Hillgene
11.3.1 Hillgene Company Information
11.3.2 Hillgene Adeno-Associated Virus (AAV) CDMO Services Product Offered
11.3.3 Hillgene Adeno-Associated Virus (AAV) CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Hillgene Main Business Overview
11.3.5 Hillgene Latest Developments
11.4 Charles River Laboratories
11.4.1 Charles River Laboratories Company Information
11.4.2 Charles River Laboratories Adeno-Associated Virus (AAV) CDMO Services Product Offered
11.4.3 Charles River Laboratories Adeno-Associated Virus (AAV) CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 Charles River Laboratories Main Business Overview
11.4.5 Charles River Laboratories Latest Developments
11.5 Ubrigene
11.5.1 Ubrigene Company Information
11.5.2 Ubrigene Adeno-Associated Virus (AAV) CDMO Services Product Offered
11.5.3 Ubrigene Adeno-Associated Virus (AAV) CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 Ubrigene Main Business Overview
11.5.5 Ubrigene Latest Developments
11.6 Obio Technology (Shanghai)
11.6.1 Obio Technology (Shanghai) Company Information
11.6.2 Obio Technology (Shanghai) Adeno-Associated Virus (AAV) CDMO Services Product Offered
11.6.3 Obio Technology (Shanghai) Adeno-Associated Virus (AAV) CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 Obio Technology (Shanghai) Main Business Overview
11.6.5 Obio Technology (Shanghai) Latest Developments
11.7 Genesail Biotech (Shanghai)
11.7.1 Genesail Biotech (Shanghai) Company Information
11.7.2 Genesail Biotech (Shanghai) Adeno-Associated Virus (AAV) CDMO Services Product Offered
11.7.3 Genesail Biotech (Shanghai) Adeno-Associated Virus (AAV) CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 Genesail Biotech (Shanghai) Main Business Overview
11.7.5 Genesail Biotech (Shanghai) Latest Developments
11.8 WuXi ATU
11.8.1 WuXi ATU Company Information
11.8.2 WuXi ATU Adeno-Associated Virus (AAV) CDMO Services Product Offered
11.8.3 WuXi ATU Adeno-Associated Virus (AAV) CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 WuXi ATU Main Business Overview
11.8.5 WuXi ATU Latest Developments
11.9 Porton Advanced Solutions
11.9.1 Porton Advanced Solutions Company Information
11.9.2 Porton Advanced Solutions Adeno-Associated Virus (AAV) CDMO Services Product Offered
11.9.3 Porton Advanced Solutions Adeno-Associated Virus (AAV) CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 Porton Advanced Solutions Main Business Overview
11.9.5 Porton Advanced Solutions Latest Developments
11.10 Pharmaron
11.10.1 Pharmaron Company Information
11.10.2 Pharmaron Adeno-Associated Virus (AAV) CDMO Services Product Offered
11.10.3 Pharmaron Adeno-Associated Virus (AAV) CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 Pharmaron Main Business Overview
11.10.5 Pharmaron Latest Developments
11.11 Asymchem Laboratories (Tianjin)
11.11.1 Asymchem Laboratories (Tianjin) Company Information
11.11.2 Asymchem Laboratories (Tianjin) Adeno-Associated Virus (AAV) CDMO Services Product Offered
11.11.3 Asymchem Laboratories (Tianjin) Adeno-Associated Virus (AAV) CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.11.4 Asymchem Laboratories (Tianjin) Main Business Overview
11.11.5 Asymchem Laboratories (Tianjin) Latest Developments
11.12 Merck
11.12.1 Merck Company Information
11.12.2 Merck Adeno-Associated Virus (AAV) CDMO Services Product Offered
11.12.3 Merck Adeno-Associated Virus (AAV) CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.12.4 Merck Main Business Overview
11.12.5 Merck Latest Developments
11.13 VectorBuilder
11.13.1 VectorBuilder Company Information
11.13.2 VectorBuilder Adeno-Associated Virus (AAV) CDMO Services Product Offered
11.13.3 VectorBuilder Adeno-Associated Virus (AAV) CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.13.4 VectorBuilder Main Business Overview
11.13.5 VectorBuilder Latest Developments
11.14 Yposkesi
11.14.1 Yposkesi Company Information
11.14.2 Yposkesi Adeno-Associated Virus (AAV) CDMO Services Product Offered
11.14.3 Yposkesi Adeno-Associated Virus (AAV) CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.14.4 Yposkesi Main Business Overview
11.14.5 Yposkesi Latest Developments
11.15 Flash Therapeutics
11.15.1 Flash Therapeutics Company Information
11.15.2 Flash Therapeutics Adeno-Associated Virus (AAV) CDMO Services Product Offered
11.15.3 Flash Therapeutics Adeno-Associated Virus (AAV) CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.15.4 Flash Therapeutics Main Business Overview
11.15.5 Flash Therapeutics Latest Developments
11.16 VIVEBiotech
11.16.1 VIVEBiotech Company Information
11.16.2 VIVEBiotech Adeno-Associated Virus (AAV) CDMO Services Product Offered
11.16.3 VIVEBiotech Adeno-Associated Virus (AAV) CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.16.4 VIVEBiotech Main Business Overview
11.16.5 VIVEBiotech Latest Developments
11.17 Miltenyi Bioindustry
11.17.1 Miltenyi Bioindustry Company Information
11.17.2 Miltenyi Bioindustry Adeno-Associated Virus (AAV) CDMO Services Product Offered
11.17.3 Miltenyi Bioindustry Adeno-Associated Virus (AAV) CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.17.4 Miltenyi Bioindustry Main Business Overview
11.17.5 Miltenyi Bioindustry Latest Developments
11.18 Genezen
11.18.1 Genezen Company Information
11.18.2 Genezen Adeno-Associated Virus (AAV) CDMO Services Product Offered
11.18.3 Genezen Adeno-Associated Virus (AAV) CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.18.4 Genezen Main Business Overview
11.18.5 Genezen Latest Developments
11.19 Miltenyi Biotec
11.19.1 Miltenyi Biotec Company Information
11.19.2 Miltenyi Biotec Adeno-Associated Virus (AAV) CDMO Services Product Offered
11.19.3 Miltenyi Biotec Adeno-Associated Virus (AAV) CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.19.4 Miltenyi Biotec Main Business Overview
11.19.5 Miltenyi Biotec Latest Developments
11.20 Exthera
11.20.1 Exthera Company Information
11.20.2 Exthera Adeno-Associated Virus (AAV) CDMO Services Product Offered
11.20.3 Exthera Adeno-Associated Virus (AAV) CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.20.4 Exthera Main Business Overview
11.20.5 Exthera Latest Developments
11.21 Catalent
11.21.1 Catalent Company Information
11.21.2 Catalent Adeno-Associated Virus (AAV) CDMO Services Product Offered
11.21.3 Catalent Adeno-Associated Virus (AAV) CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.21.4 Catalent Main Business Overview
11.21.5 Catalent Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.
